Get the Stockscreener App
3.86
8.73%
+0.31
After Hours:
3.86
Summit Therapeutics Inc stock is currently priced at $3.86, with a 24-hour trading volume of 1.38M.
It has seen a +8.73% increased in the last 24 hours and a +3.21% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.54 pivot point. If it approaches the $3.81 resistance level, significant changes may occur.
Previous Close:
$3.55
Open:
$3.63
24h Volume:
1.38M
Market Cap:
$2.71B
Revenue:
$956.00K
Net Income/Loss:
$-614.93M
P/E Ratio:
-2.2961
EPS:
-1.6811
Net Cash Flow:
$-76.89M
1W Performance:
+10.29%
1M Performance:
+3.21%
6M Performance:
+104.23%
1Y Performance:
+184.87%
1D Range:
$3.52
$3.90
52W Range:
$1.30
$5.22
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
44 12 3544 3939
Address
136a Eastern Avenue, Milton Park, Abingdon
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Why Summit Therapeutics Stock Crushed the Market This Week
The Motley Fool
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
Benzinga
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Summit Therapeutics Inc Stock (SMMT) Financials Data
Summit Therapeutics Inc (SMMT) Revenue 2024
SMMT reported a revenue (TTM) of $956.00 thousand for the quarter ending September 30, 2022, a -45.15% decline year-over-year.
Summit Therapeutics Inc (SMMT) Net Income 2024
SMMT net income (TTM) was -$614.93 million for the quarter ending December 31, 2023, a -680.54% decrease year-over-year.
Summit Therapeutics Inc (SMMT) Cash Flow 2024
SMMT recorded a free cash flow (TTM) of -$76.89 million for the quarter ending December 31, 2023, a -82.17% decrease year-over-year.
Summit Therapeutics Inc (SMMT) Earnings per Share 2024
SMMT earnings per share (TTM) was -$1.49 for the quarter ending December 31, 2023, a -263.41% decline year-over-year.
About Summit Therapeutics Inc
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
1.53%
3.38%
Cap:
|
Volume (24h):